Diabetic Neuropathy Treatment 2026: Podiatrist Guide

Medically reviewed by Dr. Tom Biernacki, DPM — Board-eligible podiatrist, Balance Foot & Ankle, Howell & Bloomfield Hills, MI

Quick Answer: Diabetic Neuropathy Treatment

Diabetic peripheral neuropathy — nerve damage from chronically elevated blood glucose — affects approximately 50% of people with diabetes and is the leading cause of lower-limb amputation in the United States. The most important treatment is aggressive glycemic control: reducing HbA1c slows progression and, in early stages, allows partial nerve recovery. Symptomatic treatment for neuropathic pain includes first-line medications (duloxetine, pregabalin, gabapentin), topical agents (capsaicin 8%, lidocaine), and physical therapy. A podiatrist is a critical part of the diabetic neuropathy care team — neuropathy eliminates the protective pain response that normally alerts you to foot injury, making regular DPM evaluation essential to prevent ulceration and amputation. See a podiatrist at least annually if you have diabetes, and immediately if you notice any foot wound, redness, or swelling.

Why Diabetic Neuropathy Requires a Podiatrist on Your Team

Most diabetic neuropathy patients understand that their feet feel different — burning, tingling, or numbness are the classic symptoms. What many do not fully appreciate is the consequence of losing protective sensation: a blister, a small wound, an ingrown toenail, or a tight shoe rubbing becomes a serious threat because the pain signal that would normally alert a non-neuropathic patient to stop walking is absent. In my practice, I see patients who have been walking on infected wounds for days without knowing it — the neuropathy silenced the alarm system.

The statistics are sobering. Diabetic neuropathy is the primary driver of the 100,000+ lower extremity amputations performed annually in the United States. Approximately 85% of these amputations are preceded by a foot ulcer — and the majority of those ulcers were preventable with appropriate foot care and regular podiatric evaluation. A routine DPM visit every 6–12 months finds problems before they escalate.

This guide covers both the systemic treatment of diabetic peripheral neuropathy (glycemic management, symptomatic medications) and the podiatric care that protects neuropathic feet from complications.

Treating the Cause: Glycemic Control

Diabetic neuropathy is caused by chronic hyperglycemia damaging small blood vessels (microangiopathy) that supply peripheral nerves and directly damaging nerve fibers through glycosylation of nerve proteins. The only disease-modifying intervention is reducing blood glucose to target levels. Everything else is symptomatic management.

The evidence on glycemic control and neuropathy is definitive. The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive glycemic control in Type 1 diabetes reduced the development of clinical neuropathy by 60% compared to conventional control. The United Kingdom Prospective Diabetes Study (UKPDS) showed similar benefit in Type 2 diabetes. Every 1% reduction in HbA1c is associated with a 40% reduction in microvascular complications, including neuropathy.

Target HbA1c for neuropathy prevention and slowing progression: less than 7.0% for most patients (American Diabetes Association guidelines), or as low as 6.5% for younger patients early in their disease without significant cardiovascular risk. Patients with established neuropathy who have had hypoglycemic unawareness may have a less aggressive target — this is individualized by their endocrinologist.

In early-stage neuropathy (abnormal nerve conduction studies, mild symptoms), aggressive glycemic control can produce partial nerve fiber recovery — small sensory fibers can regenerate at approximately 1mm per day under optimal metabolic conditions. This recovery window closes as neuropathy progresses to moderate and severe stages. Early intervention is not optional if the goal is preservation of foot sensation.

Symptomatic Treatments for Neuropathic Pain

For patients with painful diabetic neuropathy (burning, electric, stabbing, or aching pain — distinct from the numbness that characterizes advanced disease), several medications have demonstrated efficacy in randomized controlled trials.

First-Line: Duloxetine and Pregabalin

Duloxetine (Cymbalta) 60–120 mg daily is the only medication FDA-approved specifically for diabetic peripheral neuropathic pain. As a serotonin-norepinephrine reuptake inhibitor (SNRI), it modulates descending pain inhibition pathways in the spinal cord. A meta-analysis of 8 RCTs found duloxetine reduced neuropathic pain scores by approximately 50% in responders. It also has modest antidepressant effects, which is relevant given the high rate of depression comorbidity in chronic pain patients. Start at 30 mg daily for 1 week, then increase to 60 mg — the dose-response curve plateaus after 60 mg for most patients.

Pregabalin (Lyrica) 150–600 mg daily in divided doses is an alpha-2-delta calcium channel ligand that reduces neuronal excitability in sensitized pain pathways. FDA-approved for diabetic neuropathy pain. The AAN (American Academy of Neurology) guidelines rate it as established efficacy (Level A evidence) for painful diabetic neuropathy. Effective dose range: 300–600 mg/day. Titrate slowly — most side effects (sedation, dizziness, weight gain) are dose-dependent and improve with gradual titration. Pregabalin is a schedule V controlled substance due to abuse potential.

Gabapentin (Neurontin) 1800–3600 mg daily in divided doses — same mechanism as pregabalin, similar efficacy, less bioavailability (more variable absorption). Less expensive than pregabalin and available generically, making it a practical first-line choice for many patients. Titrate up over 2–4 weeks to minimize side effects.

Second-Line Options

Tricyclic antidepressants (amitriptyline, nortriptyline) 25–150 mg nightly — decades of evidence for neuropathic pain. High efficacy, but the anticholinergic and cardiac side effect profile limits use in older patients and those with cardiovascular disease. Nortriptyline has fewer anticholinergic effects than amitriptyline and is better tolerated in elderly patients. ECG screening before starting in patients over 65 or with cardiac history.

SNRIs (venlafaxine, desvenlafaxine) — similar mechanism to duloxetine with reasonable evidence for neuropathic pain. Not FDA-approved for this indication but widely used off-label when duloxetine is not tolerated.

Tramadol 50–400 mg daily — weak opioid with SNRI properties. Provides meaningful pain relief for refractory cases. Carries addiction, seizure, and serotonin syndrome risk. Reserved for patients who have failed first and second-line non-opioid options.

Topical Agents (Minimal Systemic Absorption)

Capsaicin 8% patch (Qutenza) — a high-concentration capsaicin patch applied in clinic for 30–60 minutes under topical anesthesia. Depletes substance P from sensory nerve terminals, desensitizing them to pain signals. One application provides 3–6 months of meaningful pain reduction in approximately 30% of patients. Particularly useful for patients who cannot tolerate systemic medications. Application requires supervision due to the intense burning during the procedure.

Topical lidocaine (5% patch, 4% cream) — sodium channel blockade at the application site. Limited systemic absorption. Most useful for localized areas of allodynia (pain from light touch). Available OTC in lower concentrations; prescription-strength patches (Lidoderm) require prior authorization from most insurers.

Compounded topical formulations — combinations of ketamine, gabapentin, clonidine, and/or lidocaine in a topical base. The evidence for compounded topicals is lower quality than for the single agents above, but some patients achieve meaningful relief with excellent tolerability. I use these selectively for patients who cannot manage systemic medications.

Non-Pharmacological Treatments

Physical Therapy and Exercise

Exercise is one of the most underutilized treatments for diabetic neuropathy. A 2019 RCT in Diabetes Care demonstrated that 16 weeks of aerobic exercise increased intraepidermal nerve fiber density in patients with early diabetic neuropathy — evidence of actual nerve regeneration from exercise intervention. The mechanism involves improved microvascular blood flow, reduction of systemic inflammation, and direct neurotrophic effects of exercise on peripheral nerves.

I recommend 150 minutes per week of moderate-intensity aerobic exercise for all neuropathy patients who are ambulatory — typically walking, swimming, or cycling (avoiding high-impact barefoot activities). Balance training is equally important: neuropathy impairs proprioception (the sensation of foot and ankle position in space), dramatically increasing fall risk. Single-leg balance exercises, balance board training, and Tai Chi have demonstrated fall reduction in diabetic neuropathy patients in multiple trials.

Transcutaneous Electrical Nerve Stimulation (TENS)

TENS units deliver low-voltage electrical pulses through skin electrodes, activating large-diameter sensory fibers that inhibit pain signal transmission (gate control theory). Multiple small RCTs show modest but meaningful pain reduction for painful diabetic neuropathy. TENS units are available OTC and are safe for most patients. I recommend them as an adjunct to medication rather than a substitute.

MLS Laser Therapy

Multiwave locked system (MLS) laser therapy uses dual wavelengths (808nm and 905nm) to stimulate cellular ATP production and reduce neuroinflammation in peripheral nerves. Multiple clinical studies have demonstrated improvements in neuropathic pain scores and objective measures of nerve conduction velocity in diabetic neuropathy patients after 10–12 treatment sessions. We offer MLS laser at Balance Foot & Ankle — call (810) 206-1402 for details on treatment protocols and insurance coverage.

Nutritional Supplementation

Alpha-lipoic acid (ALA) 600 mg daily — the most evidence-supported supplement for diabetic neuropathy. ALA is an antioxidant that reduces oxidative stress in peripheral nerves and has demonstrated improvement in both nerve conduction velocity and pain scores in multiple European trials (SYDNEY, ALADIN studies). Widely used in Europe as standard of care; considered adjunctive in US guidelines. Generally safe, well-tolerated, and available OTC.

B12 supplementation — essential for patients on metformin, which depletes B12 over years of use. B12 deficiency independently causes peripheral neuropathy indistinguishable from diabetic neuropathy. I check B12 levels annually on all metformin-treated neuropathy patients. Replacement: methylcobalamin 1000 mcg daily (oral or sublingual) for confirmed deficiency.

Vitamin D — observational studies consistently show inverse relationships between vitamin D levels and neuropathy severity. Repletion to 40–60 ng/mL is a low-risk intervention with potential benefit. I check 25-OH vitamin D levels in all neuropathy patients and supplement deficiency aggressively.

Podiatric Care for Neuropathic Feet: Prevention of Complications

This section is the most important for preventing amputation — the outcome every neuropathy patient must be working to avoid.

The Diabetic Foot Exam

Every neuropathic diabetic patient needs a comprehensive foot examination at least annually — more frequently (every 3–6 months) if neuropathy is moderate-to-severe or prior foot ulceration has occurred. My exam includes: monofilament testing (10g Semmes-Weinstein monofilament applied to 10 plantar sites — inability to sense 3 or more sites indicates high ulceration risk), vibration threshold testing, ankle reflexes, pulse assessment, and skin inspection for callus, fissure, and early ulceration.

Patients who cannot perceive the 10g monofilament at plantar sites are classified as high-risk and require more intensive monitoring, therapeutic footwear prescription, and patient education about daily foot inspection.

Therapeutic Footwear

Medicare’s Therapeutic Shoe Program (HCPCS codes A5500 and A5512) covers one pair of depth-inlay shoes and three pairs of inserts annually for diabetic patients with peripheral neuropathy, prior amputation, foot ulceration, callus formation, or pre-ulcerative lesions. These shoes provide extra depth for custom inserts, protected seams to reduce friction, and appropriate width for foot deformities common in neuropathic feet.

I prescribe therapeutic footwear for all neuropathic patients who qualify. Walking barefoot or in unsupportive footwear with established neuropathy is one of the highest-risk behaviors I counsel against — the neuropathic foot cannot sense a developing pressure injury until it has broken down into an ulcer.

Callus Management

Plantar callus under the metatarsal heads or heel is a high-risk finding in neuropathic feet. It represents repetitive pressure without the normal protective response of pain and behavioral modification. Left untreated, callus becomes a precursor to ulceration — the tissue underneath a thick callus is under even higher pressure than the surrounding skin, and once it breaks down, the patient often discovers the ulcer only when they notice blood in their shoe.

I debride plantar callus at every visit for high-risk neuropathic patients — a simple office procedure that demonstrably reduces peak plantar pressure and ulcer recurrence rates. Patients cannot safely debride their own callus at home (razors, scissors, or chemical callus removers carry serious injury risk without protective sensation).

Daily Foot Inspection Protocol

Every neuropathic diabetic patient should inspect their feet daily — top, bottom, and between the toes — for any changes: redness, swelling, blistering, callus, or open areas. For patients who cannot visualize the plantar surface, a mirror on the floor or a camera phone photograph works well. Any wound, regardless of size, should be evaluated by a podiatrist the same day — what looks like a minor abrasion in a neuropathic foot can become a limb-threatening infection within 48–72 hours.

Water temperature testing before bathing is equally important — neuropathic patients cannot sense scalding water and commonly sustain severe burns that become ulcers. Test water temperature with the elbow or a bath thermometer before immersing the feet.

When to See a Podiatrist

See a podiatrist the same day if you have:

• Any open wound, blister, or break in skin on the foot — regardless of size
• Unexpected redness, warmth, or swelling in the foot or ankle
• Drainage from any area of the foot
• A new black or dark area on the foot (possible tissue necrosis — emergency)
• Fever with any foot symptom

Schedule a routine appointment if you have:

• Diabetes and have not had a comprehensive foot exam in the past year
• Burning, tingling, or numbness in the feet that is new or worsening
• Thickened or painful toenails that are difficult to trim safely
• Callus or corns on the plantar foot
• Footwear that has become uncomfortable or is causing pressure areas

Balance Foot & Ankle provides comprehensive diabetic foot care — annual exams, monofilament testing, therapeutic footwear prescription, callus debridement, nail care, and wound management — at both our Howell (4330 E Grand River Ave, MI 48843) and Bloomfield Hills (43494 Woodward Ave #208, MI 48302) locations. Same-day appointments available. Call (810) 206-1402 or book online.

Frequently Asked Questions

Can diabetic neuropathy be reversed?

In early stages, yes — partial reversal is possible with aggressive glycemic control and exercise, which can stimulate small nerve fiber regeneration. Once neuropathy progresses to moderate or severe stages with established axonal loss, reversal is unlikely. The goal shifts from reversal to slowing progression and preventing complications. This is why early intervention — as soon as abnormal nerve conduction or reduced monofilament sensitivity is detected — is so important.

What is the best medication for diabetic neuropathy pain?

Duloxetine 60–120 mg daily is the only FDA-approved treatment specifically for diabetic peripheral neuropathic pain and is the first-line recommendation in most clinical guidelines. Pregabalin and gabapentin are equivalent first-line options for patients who cannot tolerate duloxetine. The choice between them depends on individual patient factors — comorbid depression (favors duloxetine), renal function (affects gabapentinoid dosing), insurance coverage, and tolerability. Most patients require a trial of 4–8 weeks at therapeutic dose before assessing effectiveness.

How do I protect my feet with diabetic neuropathy?

The five essentials: inspect your feet daily (use a mirror or camera phone for the plantar surface), never walk barefoot inside or outside, wear protective footwear with custom inserts at all times, test bathwater temperature before immersing feet, and see a podiatrist at least annually (more frequently if high-risk). Any wound or unusual change in the foot is a same-day podiatry visit — not a “watch and wait” situation.

Does Medicare cover diabetic foot care?

Yes — Medicare covers routine podiatric foot care for diabetic patients with peripheral neuropathy, every 2 months, when the patient’s primary care physician documents a diabetes-related condition requiring professional foot care. Medicare Part B also covers one pair of therapeutic shoes and three pairs of inserts annually under the Therapeutic Shoe Program. We verify Medicare coverage before your first visit — call (810) 206-1402.

How often should diabetics see a podiatrist?

The American Diabetes Association recommends annual comprehensive foot examination for all diabetic patients. For patients with peripheral neuropathy, prior ulceration, Charcot arthropathy, or current wound: every 1–3 months. For high-risk feet without active wound: every 3–6 months. The frequency depends on risk stratification — your podiatrist determines the appropriate interval at your initial visit based on exam findings.

Bottom Line

Diabetic neuropathy is a serious condition — but the complications that lead to amputation are largely preventable with appropriate care. The treatment priorities are: aggressive glycemic control (the only disease-modifying intervention), symptom management with evidence-based medications when painful neuropathy is present, and — critically — regular podiatric care to protect neuropathic feet from the wounds that cannot be felt until they have become serious.

If you have diabetes and have not had a comprehensive foot exam this year, that is the most important appointment you can schedule today. At Balance Foot & Ankle, a diabetic foot exam including monofilament testing takes approximately 30 minutes and identifies whether you are at low, intermediate, or high risk — which determines everything about your follow-up care plan.

Call (810) 206-1402 or book online. Same-day appointments in Howell and Bloomfield Hills, Michigan. Most insurance accepted.